Abstract
Less than a month after the FDA’s Janet Woodcock told biopharmaceutical executives that the agency wants to create uniform risk mitigation and evaluation strategy (REMS) components, FDA approved its first product with a standardized REMS: Abstral immediate-release fentanyl transmucosal tablets.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
